Ajanta Pharma Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 19 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹45.5K Cr

Ajanta Pharma expects continued healthy growth momentum across business segments. - India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years. - U.S. Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6). - EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5). - Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5). - U.S.

From Ajanta Pharma's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹3,639.8

Market Cap

₹45.5K Cr

P/E Ratio

40.1

How does Ajanta Pharma rank in Pharmaceuticals & Biotechnology?

Compare Ajanta Pharma against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Ajanta Pharma — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.4K Cr, net profit ₹267 Cr.

Full financials →

📊 Revenue & Sales Performance

→Ajanta Pharma expects continued healthy growth momentum across business segments.
→India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years.
→U.S. generics showed 52% growth in Q3 FY26; 8 product launches in last 12 months; double-digit growth expected in FY27 but likely at a slower pace than FY26.
→Asia branded business projected to deliver mid-single-digit to high-single-digit growth, with some softness expected in certain markets.
→Africa branded business expected to post low-double-digit growth.
→GLP-1 products set to launch in emerging markets from FY27, with first revenue expected around FY28.
→Plans to expand into new geographies (e.g., Latin America) and therapeutic segments to support growth towards $1 billion revenue.
→No abnormal sales spikes; growth seen as normal and consistent without channel filling.
→Overall guidance suggests mid-teens growth for full year FY26.

📈 Profitability & Margins

→Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6).
→EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5).
→Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5).
→U.S. business expected to have double-digit growth in FY'27, but likely slower than FY'26 (Page 6).
→India business: strong 19% growth in Q3 FY'26; new therapies (gynecology, GLP-1) expected to contribute meaningfully over next 2-3 years (Pages 13-14).
→Expansion includes increased field force and new therapeutic segments in India and internationally; some growth expected from new territories like Latin America (Pages 7,14).
→GLP-1 product revenue expected from FY'27-28 in 26 countries via partnership (Page 7).
→No specific FY'27 earnings guidance yet; to be provided in future calls (Pages 13-14).

See what Ajanta Pharma said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Capital expenditure during the 9-month period stood at Rs. 235 crores and is expected to be in line with the full-year guidance of around Rs. 300 crores. (Page 5)
→Continued strategic investment in products, brand, and people across the branded generic portfolio is ongoing, as reflected by a 24% increase in other expenses compared to last year. (Page 5)
→There is an increased thrust on acquisitions, which might influence future payout decisions and strategic direction. The Board will decide on this after Q4 results. (Page 9)
→Expansion plans include increasing field presence in existing markets, adding new therapeutic segments (with at least one new segment targeted internationally next year), and exploring new geographies such as Latin America. (Page 9)
→Investment in R&D remains steady at around 5% of total revenue to support growth and new launches. (Page 5)

💰 Fundraising & Capital Structure

→There is no specific mention of any current or planned new fundraising through debt or equity in the Q3 FY26 transcript.
→The company is increasing focus on acquisitions, which may impact dividend payout decisions.
→Board will decide on dividend or buyback after Q4 results, possibly influenced by acquisition opportunities.
→No clear guidance or plans regarding fresh equity or debt raising were disclosed.
→Expansion plans involve increasing sales force, new therapeutic segments, and new geographies, including looking seriously at Latin America.
→The company prefers to update fundraising or major financial moves closer to implementation, likely in future earnings calls.

See what Ajanta Pharma said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The provided transcript of Ajanta Pharma Limited's Jan 30, 2026 call does not explicitly mention details about the company's current or expected orderbook or pending orders. No specific figures or comments relating to order backlog or pending orders are disclosed in the available text. The discussion primarily focuses on: - Revenue growth and segments - Market expansion and sales force additions - Product launches and partnerships, especially related to GLP-1 products - Financial performance including margins, costs, and profits - Future growth strategies and geographic expansions For detailed information regarding the current or expected orderbook/pending orders, please check other parts of the full annual or quarterly report or investor presentations beyond the pages provided.

Key Metrics

How does Ajanta Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Ajanta Pharma

See full Pharmaceuticals & Biotechnology sector rankings

What Ajanta Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

ONESOURCE (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
MANKIND (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
GLAND (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
SHILPAMED (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Ajanta Pharma Q3 FY26 results?

What is Ajanta Pharma share price analysis?

Ajanta Pharma currently shows a neutral. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.

Is Ajanta Pharma planning capital expenditure?

Capital expenditure during the 9-month period stood at Rs.

Keep Ajanta Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.